Welcome to SURGE Therapeutics, the Cambridge-based biotechnology startup on a mission to revolutionize cancer treatment. Founded by Michael Goldberg and backed by an impressive $32M in Series B funding from top investors including Alumni Ventures, Khosla Ventures, Intuitive Ventures, 8VC, KdT Ventures, Pitango, and Camford Capital, SURGE is changing the landscape of cancer care. At SURGE, we relentlessly pursue a world where all cancer patients undergoing surgical tumor resection can receive intraoperative immunotherapy to prevent post-surgical recurrence and metastasis. Surgery remains the standard of care for solid tumors, yet over 40% of patients experience relapse within five years. Recent research unveiled surgery-induced inflammation's detrimental impact on the immune system, reawakening residual disease.

Built on groundbreaking research from Harvard Medical School, SURGE has developed an optimized biodegradable hydrogel that extends the release of cancer immunotherapy locally, targeting the precise site of surgical tumor resection. By focusing the effective dose at the right place and time, we trigger the patient's immune system to eliminate any remaining cancer cells, both local and distant, thereby preventing recurrence. SURGE is committed to translating this innovative approach to patients, reimagining cancer surgery, and transforming the standard of care. Never forget the driving forces behind our vision - founder Michael Goldberg and our esteemed investors. Embrace the future of cancer treatment with SURGE Therapeutics and witness the dawn of a new era in cancer care.